drugset / Trial / NCT06903715

A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)

NCT06903715

Phase 1 Completed 14 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelBasic science

Summary

Researchers designed belzutifan, the study medicine, to treat certain kinds of cancer. The goal of this study is to learn what happens to belzutifan in a healthy person's body over time when taken, by mouth, as a tablet. Researchers will learn what happens when belzutifan is taken alone and when it is taken after several days of treatment with phenytoin.

Timeline

Start
2025-03-28
Primary completion
2025-05-08
Completion
2025-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Belzutifan Small molecule Oral
Subject Phenytoin Unknown Oral

Indications

No indication recorded.